By name: genomic-cyp2c19 description: "CYP2C19 pharmacogenomics for blood thinners (Plavix/clopidogrel). Use for drug metabolism, genotype-phenotype, dosing guidance."
CYP2C19 Pharmacogenomics Skill
Overview
This skill provides guidance on CYP2C19 genetic variants and their impact on clopidogrel (Plavix) metabolism. CYP2C19 is a cytochrome P450 enzyme responsible for converting clopidogrel from a prodrug to its active metabolite.
Key Concepts
What is CYP2C19?
- Cytochrome P450 enzyme encoded by the CYP2C19 gene (chromosome 10)
- Metabolizes ~10% of clinically used drugs
- Critical for clopidogrel (Plavix) activation - converts prodrug to active antiplatelet agent
Why It Matters for Blood Thinners
Clopidogrel is a prodrug - it must be metabolized by CYP2C19 to become active. Patients with reduced CYP2C19 function have:
- Lower active drug levels
- Reduced antiplatelet effect
- Higher risk of cardiovascular events (heart attack, stroke, stent thrombosis)
CYP2C19 Phenotypes
Metabolizer Categories (CPIC Guidelines)
| Phenotype | Genotype Examples | Enzyme Activity | Clinical Impact |
|---|---|---|---|
| Ultrarapid Metabolizer (UM) | *17/*17 | Increased | Faster drug activation; may increase bleeding risk |
| Rapid Metabolizer (RM) | *1/*17 | Increased | Enhanced response |
| Normal Metabolizer (NM) | *1/*1 | Normal | Standard response |
| Intermediate Metabolizer (IM) | *1/*2, *1/*3 | Decreased | Reduced efficacy; increased CV event risk |
| Poor Metabolizer (PM) | *2/*2, *2/*3, *3/*3 | Absent/minimal | Significantly reduced efficacy; highest CV risk |
Clinical Impact by Phenotype
- Poor Metabolizers (*2/*2, *2/*3, *3/*3): Produce reduced or NO active metabolite → significantly decreased platelet inhibition → highest risk of stent thrombosis, MI, stroke
- Intermediate Metabolizers (*1/*2, *1/*3): Lowered drug response → increased risk of cardiovascular events → consider alternative therapy
- Rapid/Ultrarapid Metabolizers (*1/*17, *17/*17): Increased metabolism → higher active drug levels → may increase bleeding risk
Key Alleles (Primary Variants for Plavix Metabolism)
| Allele | Nucleotide Change | rsID | Function | Enzyme Effect |
|---|---|---|---|---|
| *1 | Wild-type | - | Normal | Normal enzyme activity |
| *2 | 681G>A | rs4244285 | Loss-of-function | Non-functional enzyme (most common LOF) |
| *3 | 636G>A | rs4986893 | Loss-of-function | Non-functional enzyme (common in Asians) |
| *17 | -806C>T | rs12248560 | Gain-of-function | Increased enzyme activity |
Variant Details
- CYP2C19*2 (rs4244285, 681G>A): The most common loss-of-function variant worldwide, causes a splicing defect resulting in a non-functional enzyme
- CYP2C19*3 (rs4986893, 636G>A): Creates a premature stop codon; primarily found in Asian populations (up to 5-10%)
- CYP2C19*17 (rs12248560, -806C>T): Promoter variant causing increased transcription and enzyme activity; may increase bleeding risk
Population Frequencies
Loss-of-function allele frequency varies significantly:
- East Asian: ~30-35% carry *2 or *3
- European: ~15-20% carry *2 or *3
- African: ~15-18% carry *2 or *3
- South Asian: ~30-40% carry *2 or *3
CPIC Treatment Recommendations
Guideline recommendations suggest alternative antiplatelet therapies (prasugrel or ticagrelor) for intermediate and poor metabolizers
For Cardiovascular Indications (ACS/PCI)
| Phenotype | Recommendation | Rationale |
|---|---|---|
| UM/RM/NM | Clopidogrel at standard dose (75mg) | Adequate active metabolite production |
| IM | Use alternative: prasugrel or ticagrelor | Reduced clopidogrel efficacy |
| PM | Use alternative: prasugrel or ticagrelor | Minimal/no active metabolite |
Alternative P2Y12 Inhibitors (Not CYP2C19 Dependent)
When clopidogrel is contraindicated due to CYP2C19 status:
- Prasugrel (Effient) - Active drug, not a CYP2C19 prodrug; contraindicated in stroke/TIA history
- Ticagrelor (Brilinta) - Reversible P2Y12 inhibitor; not dependent on CYP2C19 activation
Workflow
Step 1: Identify CYP2C19 Genotype
Check for key variants:
-- Example: Query ClinVar for CYP2C19 variants
SELECT GENESYMBOL, NAME, CLNSIG, TYPE
FROM HEALTHCARE_DATABASE.DEFAULT_SCHEMA.CLINVAR
WHERE GENESYMBOL = 'CYP2C19'
ORDER BY CLNSIG
Step 2: Determine Phenotype
Map diplotype to metabolizer status using CPIC activity scoring:
- Two normal function alleles → Normal Metabolizer
- One or two no-function alleles → Intermediate or Poor Metabolizer
- Increased function allele(s) → Rapid or Ultrarapid Metabolizer
Step 3: Apply Clinical Recommendation
Based on phenotype and indication:
- For ACS/PCI patients who are IM or PM → Recommend alternative
- For NM/UM → Standard clopidogrel therapy appropriate
Example Queries
Find CYP2C19 variants in dataset
SELECT * FROM CLINVAR WHERE GENESYMBOL = 'CYP2C19' AND CLNSIG LIKE '%athogenic%'
Link genomic data to patient outcomes
SELECT p.SUPERPOPULATION, c.DESCRIPTION as condition, COUNT(*) as count
FROM PATIENT_GENOME_MAPPING p
JOIN CONDITIONS c ON p.PATIENT_ID = c.PATIENT_ID
WHERE c.DESCRIPTION ILIKE '%thromb%' OR c.DESCRIPTION ILIKE '%stroke%'
GROUP BY p.SUPERPOPULATION, c.DESCRIPTION
When to Apply
Use this skill when:
- User mentions CYP2C19, clopidogrel, Plavix, or blood thinner metabolism
- Questions about antiplatelet therapy and genetics
- Pharmacogenomics-guided dosing for cardiovascular drugs
- Drug-gene interactions for P2Y12 inhibitors
- Queries about poor/intermediate metabolizers and drug response
References
- CPIC Guideline for CYP2C19 and Clopidogrel: 2022 Update
- PharmGKB CYP2C19 Drug-Gene Annotations
- FDA Plavix Label (CYP2C19 Poor Metabolizer Warning)